Indian Pharma Market Grows 8.7% in August, Records Rs 20,984 Crore Sales: PharmaTrac
New Delhi: The Indian Pharmaceutical Market (IPM) grew 8.7% in August 2025, reaching Rs 20,984 crore in value, according to the latest PharmaTrac Industry Report by Pharmarack.
In unit terms, the market expanded by 1.2%, underscoring steady demand despite volume stagnation. Growth in August was largely price-driven, supported by new product launches and seasonal therapies.
Therapy-wise, the respiratory segment recorded the strongest growth at 17.3%, driven by seasonal factors. Antineoplastics grew by 19.7%, while urology registered 14.6% growth. Cardiac therapies expanded by 13.2%, and blood-related therapies rose 10% in the month. Anti-diabetic therapies increased by 9.4%, while gastrointestinal products reported 7.1% growth and vitamins and minerals advanced by 5.7%. Neuro/CNS therapies grew by 8.3%, dermatology by 8.7%, and anti-infectives by 8.2%. Vaccines posted a strong rebound, growing 21.4% during the month.
At the corporate level, Sun Pharma maintained its leadership with sales of ₹19,542 crore, reflecting 13.7% growth in August. Abbott followed with ₹13,723 crore in sales, up 8.4%, while Mankind Pharma posted sales of ₹13,326 crore, registering 9.6% growth. Other leading companies including Cipla, Alkem, Intas, Torrent, Lupin, Dr. Reddy’s, and Zydus also posted healthy growth in the range of 7% to 13%. The Top 20 list additionally featured Macleods, Aristo, Emcure, GSK, Glenmark, USV, IPCA, Micro Labs, Pfizer, and Eris Lifesciences, all of which registered positive momentum in August.
At the brand level, Augmentin (GSK), Glycomet GP (USV), Pan (Alkem), and Mixtard (Abbott) continued to dominate the market in August. Himalaya’s Liv.52 grew by 13.9%, while Alkem’s Pan D rose 15.3%. Innovative therapies also performed strongly, with Abbott’s Ryzodeg up 17.4% and Thyronorm rising 16.3%. Other brands featuring in the top-selling list included Clavam, Monocef, Udiliv, Zerodol SP, Betadine, Telma, Manforce, Cilacar, Electral, Ultracet, and Duolin.
Also Read: Post-Patent Expiry Boom, Empagliflozin Sees Brand Flood, 147 Brands Launched: Pharmatrac
